title: Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma.
abstract: BACKGROUND
  Economic evaluations are increasingly relevant in order to provide support for decision makers when judging about alternative ways to allocate public funds. Aim of this study was to evaluate the economic effect of treatment with high dose sublingual immunotherapy (SLIT) in children.
  
  
  METHODS
  The study involved one allergy center, located in the north of Milan, Italy. From the existing records of patients seen for allergic disease, we extracted all children and adolescents with allergic disease, who had 1-year data prior to receiving SLIT and 3-year data on SLIT. Outcome measures (number of exacerbations, visits, absence from nursery or school), direct costs (euros spent on drugs, specialist visits, SLIT) and indirect costs (costs resulting from children school and parental work loss) were analysed. A second analysis compared a sub-group of allergic asthmatic children with a control group for costs, based on records of patients not SLIT-treated, extracted from a network-database of paediatricians.
  
  
  RESULTS
  135 patients were extracted, of which 46 had perennial, and 89 had seasonal allergy with comparable gender and age distribution. A substantial reduction was found in all outcome measures during SLIT compared with the before period. The average annual cost/patient was 2672 before SLIT initiation and _629/year during SLIT. Similar results were found for allergen subgroups. The asthma sub-analysis involved 41 children with SLIT and 35 controls. Again, SLIT patients showed a substantial reduction in outcome measures; the direct cost/patient over the whole follow-up (4 years) was _1182 for SLIT patients and _1100 for controls.
  
  
  CONCLUSIONS
  High dose SLIT may be effective in reducing the cost of allergic rhinitis and asthma and comparably expensive to conventional treatment in children with allergic asthma over a 4 years follow-up.
authors.affiliation: Pbe consulting, Verona, Italy. patrizia.berto@pbe.it
authors.forename: P
authors.initials: P
authors.lastname: Berto
authors.forename: M
authors.initials: M
authors.lastname: Bassi
authors.forename: C
authors.initials: C
authors.lastname: Incorvaia
authors.forename: F
authors.initials: F
authors.lastname: Frati
authors.forename: P
authors.initials: P
authors.lastname: Puccinelli
authors.forename: C
authors.initials: C
authors.lastname: Giaquinto
authors.forename: L
authors.initials: L
authors.lastname: Cantarutti
authors.forename: C
authors.initials: C
authors.lastname: Ortolani
mesh_terms: D000286:Administration, Sublingual; D000293:Adolescent; D000485:Allergens / Q000008:administration & dosage*; D001249:Asthma / Q000517:prevention & control*; D002648:Child; D003362:Cost-Benefit Analysis; D003888:Desensitization, Immunologic / Q000191:economics* / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*
chemical_list: D000485:Allergens